Bio-Path reports preclinical data for BP1001-A: enhanced insulin sensitivity in obesity/T2D models

BIO-PATH HOLDINGS, INC.

BP1001-A reduced Grb2 protein expression in myoblast cells and increased p-AKT and p-FOXO-1 in myoblast and hepatoma cells.
Data confirm mechanism of action via insulin/PI3K/AKT pathway; supports BP1001-A as obesity/T2D treatment.
Animal studies initiated; if successful, Phase 1 clinical trial planned for 2025.
CEO cites unmet need from existing weight-loss drugs failing in obese T2D patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.